Back to search results

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepato Cellular Carcinoma (HCC) · Hand Foot Skin Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads

  • Yu-Yun Shao, M.D., Ph.D.

    Principal Investigator

    National Taiwan University Hospital

View source on ClinicalTrials.gov(opens in a new tab)